Last reviewed · How we verify
Autologous Serum 50%
Autologous serum 50% is a patient's own blood serum diluted to 50% concentration, applied topically to provide growth factors and immunomodulatory components for tissue repair and healing.
Autologous serum 50% is a patient's own blood serum diluted to 50% concentration, applied topically to provide growth factors and immunomodulatory components for tissue repair and healing. Used for Dry eye syndrome / Ocular surface disease, Corneal epithelial defects.
At a glance
| Generic name | Autologous Serum 50% |
|---|---|
| Also known as | Autologus serum high concentration |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Autologous biological preparation |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This preparation uses the patient's own serum, which contains endogenous growth factors, cytokines, and other bioactive molecules that promote epithelial regeneration and wound healing. When applied as eye drops or topical treatment, these autologous factors reduce inflammation and support tissue remodeling. The mechanism relies on the natural healing properties present in the patient's own blood rather than a synthetic pharmacological target.
Approved indications
- Dry eye syndrome / Ocular surface disease
- Corneal epithelial defects
Common side effects
- Infection risk (contamination during preparation)
- Irritation or discomfort at application site
- Allergic reaction to serum components
Key clinical trials
- Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (PHASE3)
- Stem Cell Transplantation in Crohn's Disease (PHASE1, PHASE2)
- Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye (PHASE2)
- Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy (PHASE2)
- Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Function Impairment in Women Aged 40-50 (PHASE1, PHASE2)
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (PHASE1, PHASE2)
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (PHASE3)
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Serum 50% CI brief — competitive landscape report
- Autologous Serum 50% updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI